Results 41 to 50 of about 1,579,650 (291)

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?

open access: yesFrontiers in Immunology, 2017
PD-1–PD-L1 interaction is known to drive T cell dysfunction, which can be blocked by anti-PD-1/PD-L1 antibodies. However, studies have also shown that the function of the PD-1–PD-L1 axis is affected by the complex immunologic regulation network, and some
Zijun Y. Xu-Monette   +4 more
doaj   +1 more source

Additional file 1: of MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells

open access: yes, 2019
Figure S1. Anti-PD-L1 antibody exhibited in vivo activity on GV369-CON B-cell lymphoma. A and B: CD8+T cell percentage was enhanced, as well as CD8+T cell apoptosis and Fas expression were inhibited in GV369-CON group treated with anti-PD-L1 antibody.
Hui-Juan Zhong (799289)   +9 more
core   +1 more source

Status of PD-1 and PD-L1 expression in invasive urothelial carcinoma of the bladder with mismatch repair protein deficiency

open access: yes, 2023
It has been reported that mismatch repair deficient (d-MMR) tumors show sensitivity to immune checkpoint inhibitors. We aimed to evaluate the correlation of d-MMR and PD-1/PD-L1 expression in invasive urothelial carcinoma of the bladder.
Kıran, Merve M.   +3 more
core   +1 more source

Enhancing immunotherapy through PD‐L1 upregulation: the promising combination of anti‐PD‐L1 plus mTOR inhibitors

open access: yesMolecular Oncology
Immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein 1 (PD‐1)/programmed cell death 1 ligand 1 (PD‐L1) pathway have transformed urothelial cancer (UC) therapy.
Anna Hernández‐Prat   +16 more
doaj   +1 more source

The function and regulation of PD-L1 in immunotherapy

open access: yesADMET and DMPK, 2017
PD-L1, also known as B7-H1, is a type I transmembrane protein, which is expressed in different kinds of tumor cells. It is correlated with poor clinical outcome of patients with various types of tumors.
Libin Guo, Yao Lin, Hang Fai Kwok
doaj   +1 more source

Light-Activated Azobenzene Peptide Inhibitor of the PD-1/PD-L1 Interaction [PDF]

open access: yes
Inhibiting the protein-protein interaction between programmed cell death 1 (PD-1) and its ligand programmed cell death ligand 1 (PD-L1) has become a focal point in immunotherapy for cancer treatments.
Deanne, Hayward   +4 more
core   +2 more sources

Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA increases cytotoxicity of tumor-infiltrating lymphocytes [PDF]

open access: yes, 2019
Aim: To determine if silencing PD-1 on tumor-infiltrating lymphocytes (TILs) and its ligand-1 (PD-L1) on cancer cells will enhance the cytotoxicity of TILs.
Chen, Chen   +4 more
core   +1 more source

Smaller is better: nanobodies meet NMR

open access: yesFEBS Letters, EarlyView.
Nanobodies are single‐domain antigen‐binding fragments derived from camelid heavy chain antibodies. Their small size, high stability, and exceptional specificity make nanobodies uniquely useful probes for NMR studies of protein dynamics, transient conformational states, and protein–protein interactions.
Oleg Y. Dmitriev
wiley   +1 more source

SQSTM1/p62-mediated PD-L1 biomolecular condensate formation promotes lung tumorigenesis

open access: yesJournal of Advanced Research
Introduction: Biomolecular condensates are membraneless organelles functionally involved in diverse processes, including cancer progression. Sequestosome-1 (SQSTM1)/p62 regulates liquid–liquid phase separation to drive biomolecular condensates, while ...
Yen-Cheng Lin   +9 more
doaj   +1 more source

Image_1_Oncolytic Adenoviral Vector-Mediated Expression of an Anti-PD-L1-scFv Improves Anti-Tumoral Efficacy in a Melanoma Mouse Model.jpeg

open access: yes, 2022
Oncolytic virotherapy is an emerging therapeutic approach based on replication-competent viruses able to selectively infect and destroy cancer cells, inducing the release of tumor-associated antigens and thereby recruiting immune cells with a subsequent ...
Maria Vitale (3528125)   +11 more
core   +1 more source

Home - About - Disclaimer - Privacy